JP2010504286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504286A5 JP2010504286A5 JP2009527532A JP2009527532A JP2010504286A5 JP 2010504286 A5 JP2010504286 A5 JP 2010504286A5 JP 2009527532 A JP2009527532 A JP 2009527532A JP 2009527532 A JP2009527532 A JP 2009527532A JP 2010504286 A5 JP2010504286 A5 JP 2010504286A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- integer
- alkyl
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 0 Cc(cc1)ccc1-c1c(-c2ccccc2)nc(CNCCC*(O)O)cc1 Chemical compound Cc(cc1)ccc1-c1c(-c2ccccc2)nc(CNCCC*(O)O)cc1 0.000 description 3
- FFSLIJUQAYEYJT-UHFFFAOYSA-N CCc(cc1)ccc1-c1c(-c2ccncc2)nc(CNCCCOPO)cc1 Chemical compound CCc(cc1)ccc1-c1c(-c2ccncc2)nc(CNCCCOPO)cc1 FFSLIJUQAYEYJT-UHFFFAOYSA-N 0.000 description 2
- DSBLSVCSBKZQKP-UHFFFAOYSA-N CCc(cc1)ccc1C1=CC=C(CNCC(CC(O)=O)O)NC1C1=CCCC=C1 Chemical compound CCc(cc1)ccc1C1=CC=C(CNCC(CC(O)=O)O)NC1C1=CCCC=C1 DSBLSVCSBKZQKP-UHFFFAOYSA-N 0.000 description 2
- PKIXUSGPPGWLFE-UHFFFAOYSA-N OP(CCCNCc(cc1)nc(-c2ccccc2)c1-c1ccccc1)(O)=O Chemical compound OP(CCCNCc(cc1)nc(-c2ccccc2)c1-c1ccccc1)(O)=O PKIXUSGPPGWLFE-UHFFFAOYSA-N 0.000 description 2
- WTUCBTBLVOWQGI-UHFFFAOYSA-N CC1C(c2ccccc2)C(c2ccc(C)cc2)=CC=C(COCCCP(O)(O)=O)CC1 Chemical compound CC1C(c2ccccc2)C(c2ccc(C)cc2)=CC=C(COCCCP(O)(O)=O)CC1 WTUCBTBLVOWQGI-UHFFFAOYSA-N 0.000 description 1
- QZSGATSDHMXWLY-UHFFFAOYSA-N CCC(C=C1)=CCC1C1=CCC(CNCCCP(O)O)N=C1c1ccncc1 Chemical compound CCC(C=C1)=CCC1C1=CCC(CNCCCP(O)O)N=C1c1ccncc1 QZSGATSDHMXWLY-UHFFFAOYSA-N 0.000 description 1
- YLBFYGJECVHLDH-UHFFFAOYSA-N CCC(C=C1)=CCC1C1=CCC(COCCCP(O)O)N=C1c1ccccc1 Chemical compound CCC(C=C1)=CCC1C1=CCC(COCCCP(O)O)N=C1c1ccccc1 YLBFYGJECVHLDH-UHFFFAOYSA-N 0.000 description 1
- AIBDVDJSCMNDDG-UHFFFAOYSA-N CCCCOCC(NC1C2=CCCC=C2)=CC=C1c1ccc(C)cc1 Chemical compound CCCCOCC(NC1C2=CCCC=C2)=CC=C1c1ccc(C)cc1 AIBDVDJSCMNDDG-UHFFFAOYSA-N 0.000 description 1
- JEWGRYIRSLGDRP-UHFFFAOYSA-N CCCc(cc1)ccc1C1=CCC(CNCCCP(O)(O)=O)N=C1c1ccccc1 Chemical compound CCCc(cc1)ccc1C1=CCC(CNCCCP(O)(O)=O)N=C1c1ccccc1 JEWGRYIRSLGDRP-UHFFFAOYSA-N 0.000 description 1
- DLTIFALHRSYDKJ-UHFFFAOYSA-N CCc(cc1)ccc1-c1c(C2=CCCC=C2)nc(CNCCP(O)(O)=O)cc1 Chemical compound CCc(cc1)ccc1-c1c(C2=CCCC=C2)nc(CNCCP(O)(O)=O)cc1 DLTIFALHRSYDKJ-UHFFFAOYSA-N 0.000 description 1
- BRPCZYXCBFUTPT-UHFFFAOYSA-N CCc(cc1)ccc1C1=CC=C(CNCCP(O)(O)=O)CC1C1=CCCC=C1 Chemical compound CCc(cc1)ccc1C1=CC=C(CNCCP(O)(O)=O)CC1C1=CCCC=C1 BRPCZYXCBFUTPT-UHFFFAOYSA-N 0.000 description 1
- ONMXHBAWHRLKHR-UHFFFAOYSA-N CCc1ccc(C2C(C3=CCCC=C3)[N-]C(CNCCCP(C(O)O)=O)=CC2)cc1 Chemical compound CCc1ccc(C2C(C3=CCCC=C3)[N-]C(CNCCCP(C(O)O)=O)=CC2)cc1 ONMXHBAWHRLKHR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82480706P | 2006-09-07 | 2006-09-07 | |
| PCT/US2007/077588 WO2008030843A1 (en) | 2006-09-07 | 2007-09-05 | Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010504286A JP2010504286A (ja) | 2010-02-12 |
| JP2010504286A5 true JP2010504286A5 (enExample) | 2010-10-21 |
Family
ID=38961939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527532A Pending JP2010504286A (ja) | 2006-09-07 | 2007-09-05 | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体アゴニスト及び／又はアンタゴニスト生物活性を有するヘテロ芳香族化合物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2066633A1 (enExample) |
| JP (1) | JP2010504286A (enExample) |
| AU (1) | AU2007292347A1 (enExample) |
| BR (1) | BRPI0716815A2 (enExample) |
| CA (1) | CA2662852A1 (enExample) |
| WO (1) | WO2008030843A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005014271A1 (de) * | 2005-03-24 | 2006-09-28 | Rhein Chemie Rheinau Gmbh | Mikrogele in Kombination mit funktionalen Additiven |
| US8563594B2 (en) | 2007-05-08 | 2013-10-22 | Allergan, Inc. | S1P3 receptor inhibitors for treating pain |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| EP2342205B1 (en) | 2008-08-27 | 2016-04-20 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| IN2012DN05125A (enExample) * | 2009-11-24 | 2015-10-23 | Allergan Inc | |
| US8741875B2 (en) | 2009-11-24 | 2014-06-03 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| EP4148045A1 (en) | 2010-01-27 | 2023-03-15 | Arena Pharmaceuticals, Inc. | Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof |
| ES2558087T3 (es) | 2010-03-03 | 2016-02-01 | Arena Pharmaceuticals, Inc. | Procesos para la preparación de moduladores del receptor S1P1 y formas cristalinas de los mismos |
| WO2011133734A1 (en) | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| US8513220B2 (en) | 2010-05-14 | 2013-08-20 | Allergan, Inc. | Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity |
| WO2011143332A1 (en) | 2010-05-14 | 2011-11-17 | Allergan, Inc. | Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity |
| US9187437B2 (en) | 2010-09-24 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds |
| WO2015089182A1 (en) | 2013-12-11 | 2015-06-18 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| WO2018151834A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665159B1 (fr) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| WO1992002513A1 (en) * | 1990-08-06 | 1992-02-20 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| AU2004299456B2 (en) * | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
-
2007
- 2007-09-05 BR BRPI0716815-2A2A patent/BRPI0716815A2/pt not_active IP Right Cessation
- 2007-09-05 AU AU2007292347A patent/AU2007292347A1/en not_active Abandoned
- 2007-09-05 CA CA002662852A patent/CA2662852A1/en not_active Abandoned
- 2007-09-05 WO PCT/US2007/077588 patent/WO2008030843A1/en not_active Ceased
- 2007-09-05 EP EP07841853A patent/EP2066633A1/en not_active Withdrawn
- 2007-09-05 JP JP2009527532A patent/JP2010504286A/ja active Pending